Lipid nanoparticles, microscopic carriers composed of fatty compounds like lipids, have revolutionized drug delivery with their ability to ferry genetic material directly into cells. In this study, the OSU team engineered LNPs comprised of DC-cholesterol and a specialized ionizable lipid, 113-O12B, which exhibited a remarkable ability to bind a blood serum protein called vitronectin. This binding triggers the formation of a protein corona on the nanoparticles, a dynamic interface that actively guides the LNPs to lung tissue, and more importantly, lung tumor microenvironments.

Vitronectin’s recruitment is no coincidence. It interacts with integrin receptors—cellular docking proteins highly expressed on lung cancer cells. These integrins act as biological gateways, facilitating enhanced uptake of the therapeutic nanoparticles by tumor cells while sparing healthy tissue. This receptor-mediated targeting marks a significant advance over conventional LNPs, which commonly accumulate in the liver, limiting their therapeutic index against lung malignancies.

A key therapeutic payload in the OSU nanoparticles is the mRNA encoding follistatin, a potent protein with dual biological activity. Within the tumor microenvironment, follistatin acts as an inhibitor of tumor growth pathways, but it also plays an essential role in promoting muscle mass. This dual function is crucial, as cancer cachexia leads to extreme muscle wasting and weight loss, significantly increasing mortality risks for patients.

Through intravenous administration in murine models, the specially formulated LNPs demonstrated preferential accumulation in lung tumors, achieving approximately 2.5 times greater tumor burden reduction compared to liver-tropic LNPs. The delivery of follistatin mRNA induced local protein expression that not only suppressed tumor growth but also mitigated cachexia symptoms by preserving muscle and adipose tissues, enhancing food intake and maintaining body weight.

This dual-action approach is pioneering. Where traditional cancer therapies often ignore systemic wasting syndromes like cachexia, the OSU-developed nanoparticles tackle both the primary tumor and the debilitating muscle degradation, with no observed adverse side effects in preclinical studies. This represents a step change in integrative oncology, where combination treatment efficacy emerges from a single therapeutic platform.

Despite these promising results, the researchers caution that further preclinical testing remains essential before translation to human trials. Their findings, published in the Journal of Controlled Release, provide compelling evidence for the therapeutic potential of mRNA nanocarriers tailored for lung cancer and associated cachexia—two intertwined conditions that severely undermine patient survival and quality of life.

Dr. Oleh Taratula, one of the lead investigators, emphasized the novelty of their strategy, noting that “systemic delivery of mRNA therapeutics to lung tumors has remained a formidable challenge,” primarily due to ineffective drug accumulation and off-target organ toxicity. The incorporation of vitronectin-binding LNPs to circumvent these obstacles offers a powerful new avenue for mRNA-based therapies.

The broader context of this research highlights lung cancer as the third most common cancer in the United States and the leading cause of cancer mortality. Each year, approximately 230,000 new cases are diagnosed, with about 125,000 deaths, underscoring an urgent need for innovative treatments. The disproportionate risk among smokers amplifies public health concerns surrounding this disease.

Cachexia complicates clinical prognosis for lung cancer patients, affecting up to 30% of individuals diagnosed. It causes profound weight loss despite nutritional intake—primarily due to catabolic breakdown of skeletal muscle and loss of adipose tissue. Traditional cancer therapies have proven insufficient in addressing this syndrome, creating a critical therapeutic void.

The OSU team’s success leveraged interdisciplinary expertise spanning pharmaceutics, molecular biology, and bioengineering. Collaborative efforts included faculty members from various departments and partnerships with industry experts specializing in peptide therapies. This synergy enabled precise nanoparticle formulation and in-depth mechanistic studies to validate the targeted delivery approach.

Fundamental to the clinical relevancy of this research is the integration of ionizable lipids within the nanoparticle structure. These lipids facilitate endosomal escape—a crucial step for mRNA to reach the cytoplasm and trigger protein synthesis. The ionizable lipid 113-O12B was critical for endowing the LNPs with both stability in circulation and efficient cellular delivery potential.

From a translational perspective, the prospect of intravenous LNP administration simplifies systemic treatment regimens, improving patient compliance compared to localized delivery methods. The targeted nature of this therapeutic minimizes systemic exposure and potential immune-related adverse events, which have historically impeded mRNA therapeutic development for oncology.

The implications of this work extend beyond lung cancer and cachexia, suggesting a versatile platform adaptable for other cancers with known receptor profiles that can be exploited for tissue-specific targeting. Moreover, the demonstrated capacity to mitigate muscle wasting opens doors for treating other cachexia-associated malignancies and chronic conditions involving muscle catabolism.

As this research advances toward clinical trials, it promises to redefine therapeutic paradigms by coupling precision nanomedicine with genetic medicine, offering hope for improved outcomes and enhanced quality of life for patients afflicted by lung cancer and its severe systemic complications.

Subject of Research: Animals
Article Title: Not provided
News Publication Date: 30-Mar-2026
Web References: http://dx.doi.org/10.1016/j.jconrel.2026.114870
Image Credits: Graphic by Parinaz Ghanbari
Keywords: Lung cancer, lipid nanoparticles, mRNA delivery, follistatin, cachexia, integrin receptors, vitronectin, targeted therapy, nanoparticle drug delivery, tumor microenvironment, muscle wasting, systemic therapy

At the core of this breakthrough lies the design and synthesis of specialized nanoparticles that serve as vehicles for messenger RNA (mRNA) and gene-editing tools. Over 150 distinct material variants were synthesized and rigorously tested in preclinical models, leading to the identification of a novel class of ionizable lipopolymers optimized for pulmonary delivery. These nanocarriers efficiently encapsulate genetic payloads, ensuring their stability during transit and enabling targeted uptake by lung cells. Such precise targeting is paramount to maximizing therapeutic efficacy while minimizing off-target effects.

The team employed a sophisticated chemical strategy utilizing the split-Ugi reaction—a modular and streamlined synthetic approach—to rapidly generate a diverse library of lung-specific lipids. These custom molecules self-assemble into nanocarriers that navigate the complex lung microenvironment, overcoming biological barriers such as mucus and immune clearance. This approach not only facilitates delivery of nucleic acids of varying sizes but also provides a versatile platform adaptable for delivering a spectrum of genetic medicines to different organs.

Insights gleaned from rigorous in vivo studies using murine models demonstrated that these nanoparticle formulations not only localize genetic materials effectively within lung tissue but also exhibit a favorable safety profile. In models of lung cancer, administration of mRNA and gene-editing agents via these nanocarriers significantly attenuated tumor progression. Concurrently, in cystic fibrosis models—a disease caused by mutations in a single gene disrupting lung function—the therapy restored pulmonary performance by correcting underlying genetic defects, underscoring the translational potential.

The implications of this work extend beyond the immediate therapeutic targets. By enabling targeted activation of the immune system against malignant cells and simultaneously restoring normal function in genetic lung diseases, the technology exemplifies the dual power of next-generation genetic medicines. The elimination of harmful side effects traditionally associated with systemic therapies highlights the advanced specificity and controlled delivery inherent in this nanoparticle platform.

Central to these advances is the synthesis method itself, which accelerates the development cycle of lung-targeted therapies. The split-Ugi reaction facilitates rapid and scalable production of ionizable lipopolymers, granting researchers the agility to fine-tune lipid structures for optimal interaction with lung tissue and intracellular machinery. This synthetic flexibility empowers the rational design of nanocarriers tailored to address a broad spectrum of pulmonary disorders.

The research was published across two prominent journals, including Nature Communications and the Journal of the American Chemical Society, reflecting the interdisciplinary nature and high impact of this work. Key contributors from Oregon State University’s College of Pharmacy, led by Gaurav Sahay, coordinated efforts spanning medicinal chemistry, molecular biology, and pulmonary medicine to realize this ambitious vision.

Importantly, this novel delivery system circumvents challenges that have long impeded progress in pulmonary gene therapy, such as degradation of nucleic acids, inefficient cellular uptake, and immune rejection. By precisely engineering the physical and chemical properties of the nanocarriers, the team achieved a delicate balance—preserving the integrity of genetic cargo while promoting effective internalization by target lung cells.

The long-term goal articulated by the researchers centers on establishing a robust, adaptable platform capable of delivering diverse genetic therapies with maximal precision and minimal collateral effects. This foundational technology paves the way toward personalized respiratory medicine, where treatments can be custom-designed for specific genetic mutations or cancer subtypes, potentially revolutionizing standards of care for fatal and chronic lung diseases.

Funding and support for this research were provided by prominent institutions including the Cystic Fibrosis Foundation, the National Cancer Institute, and the National Heart, Lung, and Blood Institute, underscoring the clinical significance and urgent need for novel pulmonary therapeutics. Moreover, the team’s proactive steps toward translating this innovation are evident in the filing of provisional patents and active collaboration with biotech enterprises, bridging the gap from bench to bedside.

This landmark study heralds a new chapter in respiratory medicine, where nanotechnology converges with genetic engineering to unlock potent, disease-modifying interventions. The fusion of synthetic chemistry, targeted delivery, and genetic medicine showcased in this work sets a precedent for future therapies that could dramatically improve outcomes for millions suffering from lung ailments worldwide.

As the scientific community continues to unravel the complexities of lung biology and genetic disease, such cutting-edge platforms will be instrumental in overcoming previous therapeutic limitations. By refining and extending these approaches, researchers envisage expanding applications beyond lung cancer and cystic fibrosis to a wider spectrum of pulmonary and systemic diseases with genetic underpinnings.

In summary, the Oregon State-led team’s success in engineering ionizable lipopolymer nanoparticles through a strategic synthetic route marks a pivotal advancement in nanomedicine and gene therapy. By harnessing the power of targeted delivery and genetic precision, this technology lays the groundwork for safer, more efficient treatments that directly confront the root causes of respiratory illnesses—a breakthrough poised to reshape the future of medicine.

Subject of Research: Animals

Article Title: Synthesis of ionizable lipopolymers using split-Ugi reaction for pulmonary delivery of various size RNAs and gene editing

News Publication Date: 29-Apr-2025

Web References:

• https://www.nature.com/articles/s41467-025-59136-z
• https://pubs.acs.org/doi/10.1021/jacs.5c04123

Image Credits: Scientists have made a key breakthrough for treating respiratory diseases by developing a new drug delivery system that transports genetic therapies directly to the lungs, opening promising possibilities for patients with conditions like lung cancer and cystic fibrosis. Illustration provided by Gaurav Sahay, OSU College of Pharmacy.

Keywords: Nanoparticles, Pulmonary Delivery, Gene Therapy, Messenger RNA, Lung Cancer, Cystic Fibrosis, Ionizable Lipopolymers, Split-Ugi Reaction, Genetic Medicine, Targeted Drug Delivery, Nanomedicine, Respiratory Disease

Choriocarcinoma arises from trophoblastic cells, which are remnants of the placenta, and can occur following various reproductive events, including miscarriages, abortions, and molar pregnancies. In the United States, the incidence of choriocarcinoma is approximately four cases per 100,000 pregnancies. The disease is notorious for its rapid progression and potential to spread through the bloodstream, affecting vital organs such as the liver, lungs, and brain.

The key to this new approach lies in the polymersome’s ability to target a specific protein known as equilibrative nucleoside transporter 1 (ENT-1), which is frequently overexpressed in choriocarcinoma cells. ENT-1 plays a crucial role in various cellular functions, including the transportation of nucleosides, which are necessary for DNA and RNA synthesis. By harnessing the properties of polymersomes, the research team designed a system that can deliver a higher concentration of the chemotherapy drug methotrexate directly to the tumor cells.

Methotrexate, commonly abbreviated as MTX, is a well-established treatment for choriocarcinoma, yet its effectiveness has been hampered by poor tumor specificity and a range of side effects, including toxicity to the liver and kidneys. The innovative polymersome delivery system aims to enhance the therapeutic efficacy of MTX while reducing these unwanted adverse effects, providing a promising avenue for more effective cancer treatment.

In preclinical testing using mouse models, the research team demonstrated that connecting guanosine—a critical element in RNA biochemistry—to the surface of the polymersome significantly improved its targeting ability. This modification allowed the modified nanocarriers to selectively deliver methotrexate to the tumor sites. Remarkably, this targeted delivery mechanism resulted in an astounding 95% reduction in tumor size, showcasing the potential of the polymersome technology to revolutionize cancer therapies.

The findings underscore not only the pivotal role that targeted nanomedicine could play in the treatment of choriocarcinoma but also its potential applicability to other cancer types. Enhanced specificity provided by polymersomes could facilitate a new class of cancer therapeutics that are both effective and patient-friendly. As the research progresses into clinical trials, there is a hopeful outlook that this approach will lead to improved quality of life for patients.

The collaborative effort behind this significant study involved prominent figures in nanomedicine, including Olena Taratula, a leading researcher in the field, alongside OSU postdoctoral researcher Babak Mamnoon and Maureen Baldwin, a physician from Oregon Health & Science University. Together, their research sheds light on the urgent need for rapid diagnostic and treatment solutions tailored for women, especially those with young families who are often burdened by the challenges of a cancer diagnosis shortly after pregnancy.

The implications of this research extend beyond choriocarcinoma, suggesting that the polymersome technology may serve as a blueprint for new treatments for various malignancies where similar targeting strategies could be effective. Given the complexities of cancer biology, a versatile platform such as this could transform the landscape of cancer treatment, allowing for more personalized therapeutic approaches.

As the academic community eagerly anticipates the upcoming clinical trials, the researchers have received support from numerous institutions, including the National Institutes of Health. This backing exemplifies the potential this research holds not only for affecting change in one of the most aggressive cancers but for advancing the field of nanomedicine as a whole.

In conclusion, the emergence of polymersomes as targeted drug delivery systems marks a pivotal moment in the quest against choriocarcinoma. This study highlights the importance of interdisciplinary collaboration and innovative thinking in addressing complex health challenges. The hope is that with continued research and investment, future cancer therapies will not only be more effective but will also enhance the overall comfort and safety of treatment for patients.

Subject of Research: Choriocarcinoma Treatment
Article Title: ENT-1-Targeted Polymersomes to Enhance the Efficacy of Methotrexate in Choriocarcinoma Treatment
News Publication Date: 28-Jan-2025
Web References: Small Science
References: Cleveland Clinic Choriocarcinoma Patient Info
Image Credits: Parinaz Ghanbari
Keywords: Choriocarcinoma, Polymersomes, Methotrexate, Targeted Drug Delivery, Nanomedicine, Cancer Treatment, Oregon State University, ENT-1.